MedTrace Logo

Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917

NCT00290940 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2007-09-11

No results posted yet for this study

Summary

This study will compare glucose lowering with CS-917 compared to placebo after 3 months of treatment

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

CS-917

DRUG

metformin hydrochloride

DRUG

pioglitazone

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Completion
2007-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00290940 on ClinicalTrials.gov